Microbot Medical (MBOT) Common Equity (2010 - 2026)

Microbot Medical has reported Common Equity for 17 years, with the latest figure at $74.1 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 155.97% year-over-year to $74.1 million; the trailing twelve-month figure through Mar 2026 stood at $74.1 million (up 155.97% YoY), and the FY2025 full-year result was $77.6 million, up 2097.0% from the prior year.
• Common Equity for Q1 2026 stood at $74.1 million, down from $77.6 million in the prior quarter.
• The five-year high for Common Equity was $78.2 million in Q3 2025, with the low at $3.5 million in Q4 2024.
• Historically, Common Equity has averaged $21.6 million across 5 years, with a median of $7.4 million in 2023.
• Annual changes were most pronounced in 2022 — Common Equity slumped 69.04% — and 2025, when it surged 2097.0%.
• Microbot Medical's Common Equity stood at $7.3 million in 2022, then plunged by 38.25% to $4.5 million in 2023, then fell by 21.57% to $3.5 million in 2024, then surged by 2097.0% to $77.6 million in 2025, then declined by 4.45% to $74.1 million in 2026.
• The last three Common Equity figures came in at $74.1 million (Q1 2026), $77.6 million (Q4 2025), and $78.2 million (Q3 2025), per Business Quant data.